Key result
Greater ACHD complexity is linked to death nearly ~38 years earlier and more invasive treatments.
Why the study?
The end-of-life status, including age at death and treatment details, of patients with adult congenital heart disease remains unclear.
Cohort (n=26,438)
Yes
Patients with more complex adult congenital heart disease die at a younger age and undergo more invasive end-of-life treatments, highlighting the need for timely advance care planning.
Answers are grounded in this paper and cite their sources.
Greater ACHD complexity associated with younger death and invasive EOL care; leaves open prospective studies on advance planning timing.
BACKGROUND: The end-of-life (EOL) status, including age at death and treatment details, of patients with adult congenital heart disease (ACHD) remains unclear. This study investigated the EOL status of patients with ACHD using a nationwide Japanese database. METHODS AND RESULTS: Data on the last hospitalization of 26,438 patients with ACHD aged ≥15 years, admitted between 2013 and 2017, were included. Disease complexity (simple, moderate, or great) was classified using International Classification of Diseases, 10th Revision codes. Of the 853 deaths, 831 patients with classifiable disease complexity were evaluated for EOL status. The median age at death of patients in the simple, moderate, and great disease complexity groups was 77.0, 66.5, and 39.0 years , respectively. The treatments administered before death to patients in the simple, moderate, and great complexity groups included cardiopulmonary resuscitation (30.1%, 35.7%, and 41.9%, respectively), percutaneous cardiopulmonary support (7.2%, 16.5%, and 16.3%, respectively), and mechanical ventilation (58.7%, 72.2%, and 75.6%, respectively). Overall, 70% of patients died outside of specialized facilities, with >25% dying after ≥31 days of hospitalization. CONCLUSIONS: Nationwide data showed that patients with ACHD with greater disease complexity died at a younger age and underwent more invasive treatments before death, with many dying after ≥1 month of hospitalization. Discussing EOL options with patients at the appropriate time is important, particularly for patients with greater disease complexity.
No takes yet. Share an insight, caveat, or question.
Akiyama et al. (2023) conducted a cohort in Adult congenital heart disease (n=26,438). Greater disease complexity vs. Simple disease complexity was evaluated on Age at death (median years) (p=<0.001). Patients with adult congenital heart disease with greater disease complexity died at a younger age and underwent more invasive treatments before death.
Synapse has enriched 10 related papers. Consider them for comparative context: